Chugai Pharmaceutical Co., Ltd. (4519.T) JPX

Currency In JPY

Key Executives

Name	Title	Pay	Year Born
Osamu Okuda	President, Chief Executive Officer & Chairman	272M	1963
Shinji Hidaka	Executive Vice President	0	N/A
Kosuke Iijima	Head of PHC Solution Department	0	N/A
Tomoyuki Igawa	Vice President & Head of Research Division	0	N/A
Junichi Takano	Head of Marketing & Sales Division	0	N/A
Iwaaki Taniguchi	Senior Executive Officer, CFO, Head of Finance & Director	0	1966
Nobuya Ishii	Head of Science & Technology Intelligence Dept.	0	N/A
Shinya Takuma	VP & Head of Manufacturing Technology Division	0	N/A
Toshiya Sasai	Executive of Investor Relations Group & Corporation Communications Department	0	N/A
Yoshiyuki Yano	Executive Vice President	0	N/A
Kaori Ouchi	Executive Vice President	0	N/A
Tetsuya Yamaguchi	Executive Vice President	0	N/A

Name

Title

Pay

Year Born

Osamu Okuda

President, Chief Executive Officer & Chairman

272M

1963

Shinji Hidaka

Executive Vice President

N/A

Kosuke Iijima

Head of PHC Solution Department

N/A

Tomoyuki Igawa

Vice President & Head of Research Division

N/A

Junichi Takano

Head of Marketing & Sales Division

N/A

Iwaaki Taniguchi

Senior Executive Officer, CFO, Head of Finance & Director

1966

Nobuya Ishii

Head of Science & Technology Intelligence Dept.

N/A

Shinya Takuma

VP & Head of Manufacturing Technology Division

N/A

Toshiya Sasai

Executive of Investor Relations Group & Corporation Communications Department

N/A

Yoshiyuki Yano

Executive Vice President

N/A

Kaori Ouchi

Executive Vice President

N/A

Tetsuya Yamaguchi

Executive Vice President

N/A

Description

Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company, operating subsidiaries involved in the full lifecycle of drug development, from research and manufacturing to sales, import, and export, serving both Japanese and international markets. Its commercialized product portfolio spans several key therapeutic areas. These include a robust oncology offering with leading treatments like Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda. Additionally, it provides medications for bone health (e.g., Actemra, Edirol, Bonviva), renal conditions (such as Mircera and Oxarol), and neurological or other diverse ailments (including Hemlibra, CellCept, and Enspryng). Beyond its existing offerings, the company maintains an active research and development pipeline. This pipeline features multiple promising candidates targeting oncology, orthopedic and joint disorders, autoimmune diseases, kidney-related conditions, and various neurological or other health issues. Strategic partnerships are central to Chugai's operations, most notably a significant alliance with the Roche Group. The company also fosters collaborative research initiatives with academic institutions. Established in 1925, Chugai's headquarters are located in Tokyo, Japan, and it operates as a key subsidiary of Roche Holding Ltd.